|
|
Blood, 1 November 2003, Vol. 102, No. 9, pp. 3232-3237.
Prepublished online as a Blood First Edition Paper on July 17, 2003; DOI 10.1182/blood-2003-03-0908.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage
Kenji Soejima,
Masanori Matsumoto,
Koichi Kokame,
Hideo Yagi,
Hiromichi Ishizashi,
Hiroaki Maeda,
Chikateru Nozaki,
Toshiyuki Miyata,
Yoshihiro Fujimura, and
Tomohiro Nakagaki
From the First Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan; Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan; National Cardiovascular Center Research Institute, Osaka, Japan; and Department of Health Science, Nara Medical University, Nara, Japan.
A severe lack of von Willebrand factorcleaving protease (VWF-CP) activity can cause thrombotic thrombocytopenic purpura (TTP). This protease was recently identified as a member of the ADAMTS family, ADAMTS-13. It consists of a preproregion, a metalloprotease domain, a disintegrin-like domain, a thrombospondin type-1 motif (Tsp1), a cysteine-rich domain, a spacer domain, additional Tsp1 repeats, and CUB domains. To explore the structural and functional relationships of ADAMTS-13, we prepared here 13 sequential COOH-terminal truncated mutants and a single-point mutant (ArgGlyAsp [RGD] to ArgGlyGlu [RGE] in the cysteine-rich domain) and compared the activity of each mutant with that of the wild-type protein. The results revealed that the truncation of the cysteine-rich/spacer domains caused a remarkable reduction in VWF-CP activity. We also prepared immunoglobulin G (IgG) fractions containing inhibitory autoantibodies against ADAMTS-13 from plasma from 3 patients with acquired TTP, and we performed mapping of their epitopes using the aforementioned mutants. The major epitopes of these antibodies were found to reside within the cysteine-rich/spacer domains. These results suggest that the ADAMTS-13 cysteine-rich/spacer domains are essential for VWF-CP activity.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. E. Sadler
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
Blood,
July 1, 2008;
112(1):
11 - 18.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lammle, J. A. Kremer Hovinga, and J. N. George
Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease
Haematologica,
February 1, 2008;
93(2):
172 - 177.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Zhang, W. Pan, A. H. Rux, B. S. Sachais, and X. L. Zheng
The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow
Blood,
September 15, 2007;
110(6):
1887 - 1894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C. Desch and D. G. Motto
Thrombotic Thrombocytopenic Purpura in Humans and Mice
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2007;
27(9):
1901 - 1908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhou, E. E. Bouhassira, and H.-M. Tsai
An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers
Blood,
August 1, 2007;
110(3):
886 - 893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gendron, M. Kashiwagi, N. H. Lim, J. J. Enghild, I. B. Thogersen, C. Hughes, B. Caterson, and H. Nagase
Proteolytic Activities of Human ADAMTS-5: COMPARATIVE STUDIES WITH ADAMTS-4
J. Biol. Chem.,
June 22, 2007;
282(25):
18294 - 18306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P Riksen, B. M Luken, I. S Klasen, J. Voorberg, N. Crama, and M. van Deuren
Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship
Haematologica,
June 1, 2007;
92(6):
e74 - e76.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. T. Serrano, J. Kim, D. Wang, B. Dragulev, J. D. Shannon, H. H. Mann, G. Veit, R. Wagener, M. Koch, and J. W. Fox
The Cysteine-rich Domain of Snake Venom Metalloproteinases Is a Ligand for von Willebrand Factor A Domains: ROLE IN SUBSTRATE TARGETING*
J. Biol. Chem.,
December 29, 2006;
281(52):
39746 - 39756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Gao, P. J. Anderson, E. M. Majerus, E. A. Tuley, and J. E. Sadler
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease
PNAS,
December 12, 2006;
103(50):
19099 - 19104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Shang, X. W. Zheng, M. Niiya, and X. L. Zheng
Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts
Blood,
October 1, 2006;
108(7):
2207 - 2215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-j. Liu, W. Kong, K. Xu, Y. Luan, K. Ilalov, B. Sehgal, S. Yu, R. D. Howell, and P. E. Di Cesare
ADAMTS-12 Associates with and Degrades Cartilage Oligomeric Matrix Protein
J. Biol. Chem.,
June 9, 2006;
281(23):
15800 - 15808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner
Systemic antithrombotic effects of ADAMTS13
J. Exp. Med.,
March 20, 2006;
203(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ono, J. Mimuro, S. Madoiwa, K. Soejima, Y. Kashiwakura, A. Ishiwata, K. Takano, T. Ohmori, and Y. Sakata
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure
Blood,
January 15, 2006;
107(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Soejima, H. Nakamura, M. Hirashima, W. Morikawa, C. Nozaki, and T. Nakagaki
Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood
J. Biochem.,
January 1, 2006;
139(1):
147 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, C. Konetschny, G. Antoine, M. Rieger, and F. Scheiflinger
Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation
Blood,
January 1, 2006;
107(1):
118 - 125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Tao, Y. Peng, L. Nolasco, S. Cal, C. Lopez-Otin, R. Li, J. L. Moake, J. A. Lopez, and J.-f. Dong
Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions
Blood,
December 15, 2005;
106(13):
4139 - 4145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Zhou, L. Dong, D. Ginsburg, E. E. Bouhassira, and H.-M. Tsai
Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies: A NOVEL THERAPEUTIC STRATEGY?
J. Biol. Chem.,
December 2, 2005;
280(48):
39934 - 39941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ai, P. Smith, S. Wang, P. Zhang, and X. L. Zheng
The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor
J. Biol. Chem.,
August 19, 2005;
280(33):
29428 - 29434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Uemura, K. Tatsumi, M. Matsumoto, M. Fujimoto, T. Matsuyama, M. Ishikawa, T.-a. Iwamoto, T. Mori, A. Wanaka, H. Fukui, et al.
Localization of ADAMTS13 to the stellate cells of human liver
Blood,
August 1, 2005;
106(3):
922 - 924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Tao, Y. Wang, H. Choi, A. Bernardo, K. Nishio, J. E. Sadler, J. A. Lopez, and J.-f. Dong
Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow
Blood,
July 1, 2005;
106(1):
141 - 143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Majerus, P. J. Anderson, and J. E. Sadler
Binding of ADAMTS13 to von Willebrand Factor
J. Biol. Chem.,
June 10, 2005;
280(23):
21773 - 21778.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. B. Crawley, J. K. Lam, J. B. Rance, L. R. Mollica, J. S. O'Donnell, and D. A. Lane
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin
Blood,
February 1, 2005;
105(3):
1085 - 1093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Banno, K. Kaminaka, K. Soejima, K. Kokame, and T. Miyata
Identification of Strain-specific Variants of Mouse Adamts13 Gene Encoding von Willebrand Factor-cleaving Protease
J. Biol. Chem.,
July 16, 2004;
279(29):
30896 - 30903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lammle, P. M. Mannucci, and F. Scheiflinger
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura
Blood,
June 15, 2004;
103(12):
4514 - 4519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Pimanda, T. Ganderton, A. Maekawa, C. L. Yap, J. Lawler, G. Kershaw, C. N. Chesterman, and P. J. Hogg
Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice
J. Biol. Chem.,
May 14, 2004;
279(20):
21439 - 21448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13
Blood,
January 15, 2004;
103(2):
607 - 612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Pimanda, A. Maekawa, T. Wind, J. Paxton, C. N. Chesterman, and P. J. Hogg
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13
Blood,
January 15, 2004;
103(2):
627 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George
Recent Advances in Thrombotic Thrombocytopenic Purpura
Hematology,
January 1, 2004;
2004(1):
407 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|